Comment: The ECLIPSE trial presents a conflict between the accessibility of a blood-based “liquid biopsy” and the structural reality that it fails to detect the early lesions that make colorectal screening a preventive success. I’m excited about the possibilities of cfDNA technology, but we have to be transparent about its limitations. While an 83.1% sensitivity […]
Comment: A screening tool can only be as effective as the patient’s adherence to it. This NordICC study has been widely misrepresented as evidence of colonoscopy’s limited impact, yet that narrative relies on an intention-to-screen analysis that reflects an invitation to a procedure rather than the procedure itself. The NordICC results are a perfect example […]
Comment: A central issue in palliative oncology is the historical focus on aggressive salvage therapies that frequently lead to negative impacts on QOL rather than measurable survival gains. Metronomic capecitabine reverses this risk-benefit calculation, delivering a median overall survival of 18 months in responders while reporting no treatment-related deaths or severe toxicities. In a population […]
Comment: These findings are another, again highlight the massive, untapped potential of nutritional synergy with conventional treatment. Adding just 4,000 IU of Vitamin D3 didn’t just improve serum levels,; it translated to a tangible clinical victory—a 36% reduction in the risk of progression or death. This indicates that Vitamin D acts as a ‘force multiplier’ […]
Comment: While the synergy described here is scientifically elegant, we must contextualize the ‘vitamin’ label. The efficacy observed in this study relies on massive pharmacological dosing—equivalent to approximately 22 grams administered daily in an average human. This magnitude of exposure is not really possible to attain from oral supplementation, which begs the question – does […]
Comment: This study provides a fascinating glimpse into the potential of ‘precision nutrition’—where efficacy may depend entirely on the tumor’s specific genomic profile which we now have information on. The finding that Vitamin C intake improves survival specifically and only in KRAS and BRAF mutated tumors aligns perfectly with the known biology: these mutations upregulate […]
Comment: With the caveat that this is an abstract and not the full study, this trial is a crucial validation of the “less is more” principle that come up frequently. The significant improvement in Time to Treatment Failure (TTF) with the Fixed-Dose (7/7) schedule confirms what proponents of metronomic chemotherapy have argued for years: the […]
Comment: This systematic review is, predictably, hampered by significant heterogeneity and an insufficient number of trials, preventing any definitive conclusions. However, an optimistic signal does emerge. The review strongly reinforces the primary value proposition of metronomic chemotherapy: an exceptionally favorable safety profile, with a striking lack of severe hematological toxicity. Furthermore, despite the mixed data, […]
Comment: While this study is flawed by its retrospective design and critical selection bias, we shouldn’t discard the core hypothesis. The authors are right to call the findings preliminary, but the concept of metronomic maintenance therapy remains highly compelling. The fact that such a strong Overall Survival signal (86.8% vs. 68.5%) was detected at all, […]
COMMENT: The application to sugary drinks is obvious, however I would extend it to fruit and fruit juice consumption as well which both have high amounts of fructose and glucose, as well as sucrose. As examples: Fruit / Juice Serving Size Fructose (g) Glucose (g) Total Sugars (g) Whole Fruits Apple […]
